Kyselina (Zoledronic Acid)

• Zoledronic Acid is used in the management of bone‑related disorders characterized by excessive bone turnover.
• Osteoporosis: reduces risk of vertebral and hip fractures.
• Paget disease of bone: normalizes bone remodeling and alleviates pain.
• Bone metastases: decreases skeletal‑related events and bone pain.
• Hypercalcemia of malignancy: lowers elevated serum calcium levels.

• Zoledronic Acid binds with high affinity to hydroxyapatite crystals on bone surfaces, where it is internalized by osteoclasts. Inside the cell it inhibits the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway, preventing prenylation of small GTP‑binding proteins essential for osteoclast function, leading to reduced bone resorption and increased bone mineral density. The inhibition is long‑lasting after a single infusion, providing sustained anti‑resorptive effect.

Zoledronic Acid may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Flu‑like symptoms (fever, chills, myalgia)
• Nausea or vomiting
• Musculoskeletal pain
• Transient hypocalcemia

Serious or Rare Side Effects

• Acute phase reaction with severe fever
• Renal impairment or failure
• Osteonecrosis of the jaw
• Atypical femur fracture

When using Zoledronic Acid, several precautionary measures should be observed to minimize risk.

• Assess renal function before infusion: evaluate creatinine clearance.
• Monitor serum calcium and vitamin D status: correct deficiencies prior to dosing.
• Ensure adequate hydration: patients should be well‑hydrated before and after administration.
• Avoid concurrent nephrotoxic medications: limit use of NSAIDs, aminoglycosides, or contrast agents.
• Use with caution in patients with existing hypocalcemia: consider supplementation.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Zoledronic Acid can interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid)

• Concomitant use with other bisphosphonates: increased risk of toxicity.
• Co‑administration with nephrotoxic agents (e.g., aminoglycosides, high‑dose NSAIDs): may exacerbate renal damage.
• Simultaneous infusion of calcium or vitamin D supplements immediately before dosing: can reduce drug binding to bone.
• Use with other agents that cause severe hypocalcemia (e.g., calcitonin): may precipitate dangerous calcium drops.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs: monitor renal function.
• Antacids containing aluminum or magnesium: may affect absorption if given orally.
• Loop diuretics: watch electrolyte balance.
• Warfarin: monitor INR as bone turnover changes may affect coagulation.
• Immunosuppressants (e.g., corticosteroids): observe for increased infection risk.